NCT07044141

Brief Summary

20 patients will be enrolled. All were given narrowband UVB . 10 wil be give oral azathriopfine . 10 will be given tofacitinib

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Mar 2025

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2025

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

June 23, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 29, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2025

Completed
Last Updated

June 29, 2025

Status Verified

May 1, 2025

Enrollment Period

7 months

First QC Date

June 23, 2025

Last Update Submit

June 23, 2025

Conditions

Vitiligo

Outcome Measures

Primary Outcomes (1)

  • VASI improvement upto 50%

    Study will be considered efficacious if 50% improvement in VASI from baseline is seen by end of 6 months of study

    6 months

Study Arms (2)

Group A

ACTIVE COMPARATOR

Azathioprine is an immunomodulator used in treatment of vitiligo

Drug: Azathioprine

Group B

ACTIVE COMPARATOR

Tofacitinib It is a Janu kinase pathway inhibitor

Drug: Tofacitinib

Interventions

AzathioprineDRUG

azathioprine 50mg twice daily will be given

Group A
TofacitinibDRUG

It is a janus kinase inhibitor

Group B

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • patient of vitiligo with any VASI both genders 18 to 60yrs

You may not qualify if:

  • pregnancy/lactation Hyerlipidrmia Patient on immunemodulator Histry pf tuberculosis Immunocompromised patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lahore general.hospital

Lahore, Punjab Province, Pakistan

Location

MeSH Terms

Conditions

Vitiligo

Interventions

Azathioprinetofacitinib

Condition Hierarchy (Ancestors)

HypopigmentationPigmentation DisordersSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

ThionucleosidesSulfur CompoundsOrganic ChemicalsMercaptopurinePurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsNucleosidesNucleic Acids, Nucleotides, and Nucleosides

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr saadiya siddiqui

Study Record Dates

First Submitted

June 23, 2025

First Posted

June 29, 2025

Study Start

March 1, 2025

Primary Completion

September 30, 2025

Study Completion

September 30, 2025

Last Updated

June 29, 2025

Record last verified: 2025-05

Locations

PA(1)